source
- CG Oncology's bladder cancer immunotherapy cuts tumor recurrence risk by 68% in studyCG Oncology reported that its bladder cancer immunotherapy, cretostimogene, achieved a 68% reduction in tumor recurrence compared with standard care. The treatment uses an engineered common cold v…
- Eli Lilly to acquire Calytrix Bio for up to $1.5B, targeting rare blood cancersEli Lilly announced it will acquire Calytrix Bio, a Massachusetts biotech, in a deal valued at up to $1.5 billion. Calytrix focuses on precision therapies for myeloproliferative neoplasms, includi…